

Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)

Catalog Number: PKSM040597

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Mouse
Source	HEK293 Cells-derived Mouse VEGFR3/FLT4 protein Met 1-Glu 775, with an C-terminal hFc
Calculated MW	112 kDa
Observed MW	150&85&65 kDa
Accession	P35917-1
Bio-activity	1. Measured by its ability to bind human VEGF-D and mouse FIGF-His in functional ELISA. 2. Immobilized human VEGF-C at 10 µg/mL (100 µL/well) can bind mouse VEGFR3-Fc. The EC ₅₀ of mouse VEGFR3-Fc is 0.008 µg/mL.

Properties

Purity	> 92 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 92 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.